Global Next Generation Antibody Therapeutics Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Description

Building on the huge success of monoclonal antibody therapeutics, the next generation of antibody-based products such as Antibody Drug Conjugate (ADC) and Bispecific Antibody (BsAb) is now opening up new opportunities.

According to our (Global Info Research) latest study, the global Next Generation Antibody Therapeutics market size was valued at US$ 12610 million in 2023 and is forecast to a readjusted size of USD 43900 million by 2030 with a CAGR of 19.5% during review period.

The global next-generation antibody therapeutics market is expected to grow significantly over the next decade, driven by the increasing prevalence of cancer, autoimmune diseases, and infectious diseases, along with advancements in biotechnology. Oncology will remain the largest segment, but there will be strong growth in autoimmune diseases, infectious diseases, and neurological conditions.

In conclusion, technological advancements, regulatory support, and the increasing use of antibodies in combination therapies will continue to fuel the market's growth, making next-gen antibody therapeutics one of the most promising areas in biopharmaceutical innovation.Global key players of next generation antibody therapeutics include Roche, Seagen, Amgen, Pfizer, Takeda, etc. The top two players hold a share over 70%. North America is the largest market, has a share about 65%, followed by Europe and Asia-Pacific, with share 16% and 15%, separately. In terms of product type, Antibody Drug Conjugate (ADC) is the largest segment, occupied for a share of 60%, and in terms of application, Cancer has a share about 66 %.

This report is a detailed and comprehensive analysis for global Next Generation Antibody Therapeutics market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.

Key Features:
Global Next Generation Antibody Therapeutics market size and forecasts, in consumption value ($ Million), 2019-2030
Global Next Generation Antibody Therapeutics market size and forecasts by region and country, in consumption value ($ Million), 2019-2030
Global Next Generation Antibody Therapeutics market size and forecasts, by Type and by Application, in consumption value ($ Million), 2019-2030
Global Next Generation Antibody Therapeutics market shares of main players, in revenue ($ Million), 2019-2024
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Next Generation Antibody Therapeutics
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Next Generation Antibody Therapeutics market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche, Amgen, Pfizer, Takeda, Daiichi Sankyo, Seagen, Astellas, Immunomedics, GSK, Immunocore, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market segmentation
Next Generation Antibody Therapeutics market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segmentation
Next Generation Antibody Therapeutics market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
    Antibody Drug Conjugate (ADC)
    Bispecific Antibody (BsAb)

Market segment by Application
    Cancer
    Haemophilia
    Other Non-Cancer Diseases

Market segment by players, this report covers
    Roche
    Amgen
    Pfizer
    Takeda
    Daiichi Sankyo
    Seagen
    Astellas
    Immunomedics
    GSK
    Immunocore
    ADC Therapeutics

Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Next Generation Antibody Therapeutics product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Next Generation Antibody Therapeutics, with revenue, gross margin, and global market share of Next Generation Antibody Therapeutics from 2019 to 2024.
Chapter 3, the Next Generation Antibody Therapeutics competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Next Generation Antibody Therapeutics market forecast, by regions, by Type and by Application, with consumption value, from 2024 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Next Generation Antibody Therapeutics.
Chapter 13, to describe Next Generation Antibody Therapeutics research findings and conclusion.

Table of Contents

1 Market Overview
    1.1 Product Overview and Scope
    1.2 Market Estimation Caveats and Base Year
    1.3 Classification of Next Generation Antibody Therapeutics by Type
        1.3.1 Overview: Global Next Generation Antibody Therapeutics Market Size by Type: 2019 Versus 2023 Versus 2030
        1.3.2 Global Next Generation Antibody Therapeutics Consumption Value Market Share by Type in 2023
        1.3.3 Antibody Drug Conjugate (ADC)
        1.3.4 Bispecific Antibody (BsAb)
    1.4 Global Next Generation Antibody Therapeutics Market by Application
        1.4.1 Overview: Global Next Generation Antibody Therapeutics Market Size by Application: 2019 Versus 2023 Versus 2030
        1.4.2 Cancer
        1.4.3 Haemophilia
        1.4.4 Other Non-Cancer Diseases
    1.5 Global Next Generation Antibody Therapeutics Market Size & Forecast
    1.6 Global Next Generation Antibody Therapeutics Market Size and Forecast by Region
        1.6.1 Global Next Generation Antibody Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
        1.6.2 Global Next Generation Antibody Therapeutics Market Size by Region, (2019-2030)
        1.6.3 North America Next Generation Antibody Therapeutics Market Size and Prospect (2019-2030)
        1.6.4 Europe Next Generation Antibody Therapeutics Market Size and Prospect (2019-2030)
        1.6.5 Asia-Pacific Next Generation Antibody Therapeutics Market Size and Prospect (2019-2030)
        1.6.6 South America Next Generation Antibody Therapeutics Market Size and Prospect (2019-2030)
        1.6.7 Middle East & Africa Next Generation Antibody Therapeutics Market Size and Prospect (2019-2030)

2 Company Profiles
    2.1 Roche
        2.1.1 Roche Details
        2.1.2 Roche Major Business
        2.1.3 Roche Next Generation Antibody Therapeutics Product and Solutions
        2.1.4 Roche Next Generation Antibody Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
        2.1.5 Roche Recent Developments and Future Plans
    2.2 Amgen
        2.2.1 Amgen Details
        2.2.2 Amgen Major Business
        2.2.3 Amgen Next Generation Antibody Therapeutics Product and Solutions
        2.2.4 Amgen Next Generation Antibody Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
        2.2.5 Amgen Recent Developments and Future Plans
    2.3 Pfizer
        2.3.1 Pfizer Details
        2.3.2 Pfizer Major Business
        2.3.3 Pfizer Next Generation Antibody Therapeutics Product and Solutions
        2.3.4 Pfizer Next Generation Antibody Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
        2.3.5 Pfizer Recent Developments and Future Plans
    2.4 Takeda
        2.4.1 Takeda Details
        2.4.2 Takeda Major Business
        2.4.3 Takeda Next Generation Antibody Therapeutics Product and Solutions
        2.4.4 Takeda Next Generation Antibody Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
        2.4.5 Takeda Recent Developments and Future Plans
    2.5 Daiichi Sankyo
        2.5.1 Daiichi Sankyo Details
        2.5.2 Daiichi Sankyo Major Business
        2.5.3 Daiichi Sankyo Next Generation Antibody Therapeutics Product and Solutions
        2.5.4 Daiichi Sankyo Next Generation Antibody Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
        2.5.5 Daiichi Sankyo Recent Developments and Future Plans
    2.6 Seagen
        2.6.1 Seagen Details
        2.6.2 Seagen Major Business
        2.6.3 Seagen Next Generation Antibody Therapeutics Product and Solutions
        2.6.4 Seagen Next Generation Antibody Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
        2.6.5 Seagen Recent Developments and Future Plans
    2.7 Astellas
        2.7.1 Astellas Details
        2.7.2 Astellas Major Business
        2.7.3 Astellas Next Generation Antibody Therapeutics Product and Solutions
        2.7.4 Astellas Next Generation Antibody Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
        2.7.5 Astellas Recent Developments and Future Plans
    2.8 Immunomedics
        2.8.1 Immunomedics Details
        2.8.2 Immunomedics Major Business
        2.8.3 Immunomedics Next Generation Antibody Therapeutics Product and Solutions
        2.8.4 Immunomedics Next Generation Antibody Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
        2.8.5 Immunomedics Recent Developments and Future Plans
    2.9 GSK
        2.9.1 GSK Details
        2.9.2 GSK Major Business
        2.9.3 GSK Next Generation Antibody Therapeutics Product and Solutions
        2.9.4 GSK Next Generation Antibody Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
        2.9.5 GSK Recent Developments and Future Plans
    2.10 Immunocore
        2.10.1 Immunocore Details
        2.10.2 Immunocore Major Business
        2.10.3 Immunocore Next Generation Antibody Therapeutics Product and Solutions
        2.10.4 Immunocore Next Generation Antibody Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
        2.10.5 Immunocore Recent Developments and Future Plans
    2.11 ADC Therapeutics
        2.11.1 ADC Therapeutics Details
        2.11.2 ADC Therapeutics Major Business
        2.11.3 ADC Therapeutics Next Generation Antibody Therapeutics Product and Solutions
        2.11.4 ADC Therapeutics Next Generation Antibody Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
        2.11.5 ADC Therapeutics Recent Developments and Future Plans

3 Market Competition, by Players
    3.1 Global Next Generation Antibody Therapeutics Revenue and Share by Players (2019-2024)
    3.2 Market Share Analysis (2023)
        3.2.1 Market Share of Next Generation Antibody Therapeutics by Company Revenue
        3.2.2 Top 3 Next Generation Antibody Therapeutics Players Market Share in 2023
        3.2.3 Top 6 Next Generation Antibody Therapeutics Players Market Share in 2023
    3.3 Next Generation Antibody Therapeutics Market: Overall Company Footprint Analysis
        3.3.1 Next Generation Antibody Therapeutics Market: Region Footprint
        3.3.2 Next Generation Antibody Therapeutics Market: Company Product Type Footprint
        3.3.3 Next Generation Antibody Therapeutics Market: Company Product Application Footprint
    3.4 New Market Entrants and Barriers to Market Entry
    3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type
    4.1 Global Next Generation Antibody Therapeutics Consumption Value and Market Share by Type (2019-2024)
    4.2 Global Next Generation Antibody Therapeutics Market Forecast by Type (2025-2030)

5 Market Size Segment by Application
    5.1 Global Next Generation Antibody Therapeutics Consumption Value Market Share by Application (2019-2024)
    5.2 Global Next Generation Antibody Therapeutics Market Forecast by Application (2025-2030)

6 North America
    6.1 North America Next Generation Antibody Therapeutics Consumption Value by Type (2019-2030)
    6.2 North America Next Generation Antibody Therapeutics Market Size by Application (2019-2030)
    6.3 North America Next Generation Antibody Therapeutics Market Size by Country
        6.3.1 North America Next Generation Antibody Therapeutics Consumption Value by Country (2019-2030)
        6.3.2 United States Next Generation Antibody Therapeutics Market Size and Forecast (2019-2030)
        6.3.3 Canada Next Generation Antibody Therapeutics Market Size and Forecast (2019-2030)
        6.3.4 Mexico Next Generation Antibody Therapeutics Market Size and Forecast (2019-2030)

7 Europe
    7.1 Europe Next Generation Antibody Therapeutics Consumption Value by Type (2019-2030)
    7.2 Europe Next Generation Antibody Therapeutics Consumption Value by Application (2019-2030)
    7.3 Europe Next Generation Antibody Therapeutics Market Size by Country
        7.3.1 Europe Next Generation Antibody Therapeutics Consumption Value by Country (2019-2030)
        7.3.2 Germany Next Generation Antibody Therapeutics Market Size and Forecast (2019-2030)
        7.3.3 France Next Generation Antibody Therapeutics Market Size and Forecast (2019-2030)
        7.3.4 United Kingdom Next Generation Antibody Therapeutics Market Size and Forecast (2019-2030)
        7.3.5 Russia Next Generation Antibody Therapeutics Market Size and Forecast (2019-2030)
        7.3.6 Italy Next Generation Antibody Therapeutics Market Size and Forecast (2019-2030)

8 Asia-Pacific
    8.1 Asia-Pacific Next Generation Antibody Therapeutics Consumption Value by Type (2019-2030)
    8.2 Asia-Pacific Next Generation Antibody Therapeutics Consumption Value by Application (2019-2030)
    8.3 Asia-Pacific Next Generation Antibody Therapeutics Market Size by Region
        8.3.1 Asia-Pacific Next Generation Antibody Therapeutics Consumption Value by Region (2019-2030)
        8.3.2 China Next Generation Antibody Therapeutics Market Size and Forecast (2019-2030)
        8.3.3 Japan Next Generation Antibody Therapeutics Market Size and Forecast (2019-2030)
        8.3.4 South Korea Next Generation Antibody Therapeutics Market Size and Forecast (2019-2030)
        8.3.5 India Next Generation Antibody Therapeutics Market Size and Forecast (2019-2030)
        8.3.6 Southeast Asia Next Generation Antibody Therapeutics Market Size and Forecast (2019-2030)
        8.3.7 Australia Next Generation Antibody Therapeutics Market Size and Forecast (2019-2030)

9 South America
    9.1 South America Next Generation Antibody Therapeutics Consumption Value by Type (2019-2030)
    9.2 South America Next Generation Antibody Therapeutics Consumption Value by Application (2019-2030)
    9.3 South America Next Generation Antibody Therapeutics Market Size by Country
        9.3.1 South America Next Generation Antibody Therapeutics Consumption Value by Country (2019-2030)
        9.3.2 Brazil Next Generation Antibody Therapeutics Market Size and Forecast (2019-2030)
        9.3.3 Argentina Next Generation Antibody Therapeutics Market Size and Forecast (2019-2030)

10 Middle East & Africa
    10.1 Middle East & Africa Next Generation Antibody Therapeutics Consumption Value by Type (2019-2030)
    10.2 Middle East & Africa Next Generation Antibody Therapeutics Consumption Value by Application (2019-2030)
    10.3 Middle East & Africa Next Generation Antibody Therapeutics Market Size by Country
        10.3.1 Middle East & Africa Next Generation Antibody Therapeutics Consumption Value by Country (2019-2030)
        10.3.2 Turkey Next Generation Antibody Therapeutics Market Size and Forecast (2019-2030)
        10.3.3 Saudi Arabia Next Generation Antibody Therapeutics Market Size and Forecast (2019-2030)
        10.3.4 UAE Next Generation Antibody Therapeutics Market Size and Forecast (2019-2030)

11 Market Dynamics
    11.1 Next Generation Antibody Therapeutics Market Drivers
    11.2 Next Generation Antibody Therapeutics Market Restraints
    11.3 Next Generation Antibody Therapeutics Trends Analysis
    11.4 Porters Five Forces Analysis
        11.4.1 Threat of New Entrants
        11.4.2 Bargaining Power of Suppliers
        11.4.3 Bargaining Power of Buyers
        11.4.4 Threat of Substitutes
        11.4.5 Competitive Rivalry

12 Industry Chain Analysis
    12.1 Next Generation Antibody Therapeutics Industry Chain
    12.2 Next Generation Antibody Therapeutics Upstream Analysis
    12.3 Next Generation Antibody Therapeutics Midstream Analysis
    12.4 Next Generation Antibody Therapeutics Downstream Analysis

13 Research Findings and Conclusion

14 Appendix
    14.1 Methodology
    14.2 Research Process and Data Source
    14.3 Disclaimer

Table of Figures

List of Tables
 Table 1. Global Next Generation Antibody Therapeutics Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
 Table 2. Global Next Generation Antibody Therapeutics Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
 Table 3. Global Next Generation Antibody Therapeutics Consumption Value by Region (2019-2024) & (USD Million)
 Table 4. Global Next Generation Antibody Therapeutics Consumption Value by Region (2025-2030) & (USD Million)
 Table 5. Roche Company Information, Head Office, and Major Competitors
 Table 6. Roche Major Business
 Table 7. Roche Next Generation Antibody Therapeutics Product and Solutions
 Table 8. Roche Next Generation Antibody Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 9. Roche Recent Developments and Future Plans
 Table 10. Amgen Company Information, Head Office, and Major Competitors
 Table 11. Amgen Major Business
 Table 12. Amgen Next Generation Antibody Therapeutics Product and Solutions
 Table 13. Amgen Next Generation Antibody Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 14. Amgen Recent Developments and Future Plans
 Table 15. Pfizer Company Information, Head Office, and Major Competitors
 Table 16. Pfizer Major Business
 Table 17. Pfizer Next Generation Antibody Therapeutics Product and Solutions
 Table 18. Pfizer Next Generation Antibody Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 19. Takeda Company Information, Head Office, and Major Competitors
 Table 20. Takeda Major Business
 Table 21. Takeda Next Generation Antibody Therapeutics Product and Solutions
 Table 22. Takeda Next Generation Antibody Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 23. Takeda Recent Developments and Future Plans
 Table 24. Daiichi Sankyo Company Information, Head Office, and Major Competitors
 Table 25. Daiichi Sankyo Major Business
 Table 26. Daiichi Sankyo Next Generation Antibody Therapeutics Product and Solutions
 Table 27. Daiichi Sankyo Next Generation Antibody Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 28. Daiichi Sankyo Recent Developments and Future Plans
 Table 29. Seagen Company Information, Head Office, and Major Competitors
 Table 30. Seagen Major Business
 Table 31. Seagen Next Generation Antibody Therapeutics Product and Solutions
 Table 32. Seagen Next Generation Antibody Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 33. Seagen Recent Developments and Future Plans
 Table 34. Astellas Company Information, Head Office, and Major Competitors
 Table 35. Astellas Major Business
 Table 36. Astellas Next Generation Antibody Therapeutics Product and Solutions
 Table 37. Astellas Next Generation Antibody Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 38. Astellas Recent Developments and Future Plans
 Table 39. Immunomedics Company Information, Head Office, and Major Competitors
 Table 40. Immunomedics Major Business
 Table 41. Immunomedics Next Generation Antibody Therapeutics Product and Solutions
 Table 42. Immunomedics Next Generation Antibody Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 43. Immunomedics Recent Developments and Future Plans
 Table 44. GSK Company Information, Head Office, and Major Competitors
 Table 45. GSK Major Business
 Table 46. GSK Next Generation Antibody Therapeutics Product and Solutions
 Table 47. GSK Next Generation Antibody Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 48. GSK Recent Developments and Future Plans
 Table 49. Immunocore Company Information, Head Office, and Major Competitors
 Table 50. Immunocore Major Business
 Table 51. Immunocore Next Generation Antibody Therapeutics Product and Solutions
 Table 52. Immunocore Next Generation Antibody Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 53. Immunocore Recent Developments and Future Plans
 Table 54. ADC Therapeutics Company Information, Head Office, and Major Competitors
 Table 55. ADC Therapeutics Major Business
 Table 56. ADC Therapeutics Next Generation Antibody Therapeutics Product and Solutions
 Table 57. ADC Therapeutics Next Generation Antibody Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 58. ADC Therapeutics Recent Developments and Future Plans
 Table 59. Global Next Generation Antibody Therapeutics Revenue (USD Million) by Players (2019-2024)
 Table 60. Global Next Generation Antibody Therapeutics Revenue Share by Players (2019-2024)
 Table 61. Breakdown of Next Generation Antibody Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3)
 Table 62. Market Position of Players in Next Generation Antibody Therapeutics, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2023
 Table 63. Head Office of Key Next Generation Antibody Therapeutics Players
 Table 64. Next Generation Antibody Therapeutics Market: Company Product Type Footprint
 Table 65. Next Generation Antibody Therapeutics Market: Company Product Application Footprint
 Table 66. Next Generation Antibody Therapeutics New Market Entrants and Barriers to Market Entry
 Table 67. Next Generation Antibody Therapeutics Mergers, Acquisition, Agreements, and Collaborations
 Table 68. Global Next Generation Antibody Therapeutics Consumption Value (USD Million) by Type (2019-2024)
 Table 69. Global Next Generation Antibody Therapeutics Consumption Value Share by Type (2019-2024)
 Table 70. Global Next Generation Antibody Therapeutics Consumption Value Forecast by Type (2025-2030)
 Table 71. Global Next Generation Antibody Therapeutics Consumption Value by Application (2019-2024)
 Table 72. Global Next Generation Antibody Therapeutics Consumption Value Forecast by Application (2025-2030)
 Table 73. North America Next Generation Antibody Therapeutics Consumption Value by Type (2019-2024) & (USD Million)
 Table 74. North America Next Generation Antibody Therapeutics Consumption Value by Type (2025-2030) & (USD Million)
 Table 75. North America Next Generation Antibody Therapeutics Consumption Value by Application (2019-2024) & (USD Million)
 Table 76. North America Next Generation Antibody Therapeutics Consumption Value by Application (2025-2030) & (USD Million)
 Table 77. North America Next Generation Antibody Therapeutics Consumption Value by Country (2019-2024) & (USD Million)
 Table 78. North America Next Generation Antibody Therapeutics Consumption Value by Country (2025-2030) & (USD Million)
 Table 79. Europe Next Generation Antibody Therapeutics Consumption Value by Type (2019-2024) & (USD Million)
 Table 80. Europe Next Generation Antibody Therapeutics Consumption Value by Type (2025-2030) & (USD Million)
 Table 81. Europe Next Generation Antibody Therapeutics Consumption Value by Application (2019-2024) & (USD Million)
 Table 82. Europe Next Generation Antibody Therapeutics Consumption Value by Application (2025-2030) & (USD Million)
 Table 83. Europe Next Generation Antibody Therapeutics Consumption Value by Country (2019-2024) & (USD Million)
 Table 84. Europe Next Generation Antibody Therapeutics Consumption Value by Country (2025-2030) & (USD Million)
 Table 85. Asia-Pacific Next Generation Antibody Therapeutics Consumption Value by Type (2019-2024) & (USD Million)
 Table 86. Asia-Pacific Next Generation Antibody Therapeutics Consumption Value by Type (2025-2030) & (USD Million)
 Table 87. Asia-Pacific Next Generation Antibody Therapeutics Consumption Value by Application (2019-2024) & (USD Million)
 Table 88. Asia-Pacific Next Generation Antibody Therapeutics Consumption Value by Application (2025-2030) & (USD Million)
 Table 89. Asia-Pacific Next Generation Antibody Therapeutics Consumption Value by Region (2019-2024) & (USD Million)
 Table 90. Asia-Pacific Next Generation Antibody Therapeutics Consumption Value by Region (2025-2030) & (USD Million)
 Table 91. South America Next Generation Antibody Therapeutics Consumption Value by Type (2019-2024) & (USD Million)
 Table 92. South America Next Generation Antibody Therapeutics Consumption Value by Type (2025-2030) & (USD Million)
 Table 93. South America Next Generation Antibody Therapeutics Consumption Value by Application (2019-2024) & (USD Million)
 Table 94. South America Next Generation Antibody Therapeutics Consumption Value by Application (2025-2030) & (USD Million)
 Table 95. South America Next Generation Antibody Therapeutics Consumption Value by Country (2019-2024) & (USD Million)
 Table 96. South America Next Generation Antibody Therapeutics Consumption Value by Country (2025-2030) & (USD Million)
 Table 97. Middle East & Africa Next Generation Antibody Therapeutics Consumption Value by Type (2019-2024) & (USD Million)
 Table 98. Middle East & Africa Next Generation Antibody Therapeutics Consumption Value by Type (2025-2030) & (USD Million)
 Table 99. Middle East & Africa Next Generation Antibody Therapeutics Consumption Value by Application (2019-2024) & (USD Million)
 Table 100. Middle East & Africa Next Generation Antibody Therapeutics Consumption Value by Application (2025-2030) & (USD Million)
 Table 101. Middle East & Africa Next Generation Antibody Therapeutics Consumption Value by Country (2019-2024) & (USD Million)
 Table 102. Middle East & Africa Next Generation Antibody Therapeutics Consumption Value by Country (2025-2030) & (USD Million)
 Table 103. Global Key Players of Next Generation Antibody Therapeutics Upstream (Raw Materials)
 Table 104. Global Next Generation Antibody Therapeutics Typical Customers


List of Figures
 Figure 1. Next Generation Antibody Therapeutics Picture
 Figure 2. Global Next Generation Antibody Therapeutics Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
 Figure 3. Global Next Generation Antibody Therapeutics Consumption Value Market Share by Type in 2023
 Figure 4. Antibody Drug Conjugate (ADC)
 Figure 5. Bispecific Antibody (BsAb)
 Figure 6. Global Next Generation Antibody Therapeutics Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
 Figure 7. Next Generation Antibody Therapeutics Consumption Value Market Share by Application in 2023
 Figure 8. Cancer Picture
 Figure 9. Haemophilia Picture
 Figure 10. Other Non-Cancer Diseases Picture
 Figure 11. Global Next Generation Antibody Therapeutics Consumption Value, (USD Million): 2019 & 2023 & 2030
 Figure 12. Global Next Generation Antibody Therapeutics Consumption Value and Forecast (2019-2030) & (USD Million)
 Figure 13. Global Market Next Generation Antibody Therapeutics Consumption Value (USD Million) Comparison by Region (2019 VS 2023 VS 2030)
 Figure 14. Global Next Generation Antibody Therapeutics Consumption Value Market Share by Region (2019-2030)
 Figure 15. Global Next Generation Antibody Therapeutics Consumption Value Market Share by Region in 2023
 Figure 16. North America Next Generation Antibody Therapeutics Consumption Value (2019-2030) & (USD Million)
 Figure 17. Europe Next Generation Antibody Therapeutics Consumption Value (2019-2030) & (USD Million)
 Figure 18. Asia-Pacific Next Generation Antibody Therapeutics Consumption Value (2019-2030) & (USD Million)
 Figure 19. South America Next Generation Antibody Therapeutics Consumption Value (2019-2030) & (USD Million)
 Figure 20. Middle East & Africa Next Generation Antibody Therapeutics Consumption Value (2019-2030) & (USD Million)
 Figure 21. Company Three Recent Developments and Future Plans
 Figure 22. Global Next Generation Antibody Therapeutics Revenue Share by Players in 2023
 Figure 23. Next Generation Antibody Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2023
 Figure 24. Market Share of Next Generation Antibody Therapeutics by Player Revenue in 2023
 Figure 25. Top 3 Next Generation Antibody Therapeutics Players Market Share in 2023
 Figure 26. Top 6 Next Generation Antibody Therapeutics Players Market Share in 2023
 Figure 27. Global Next Generation Antibody Therapeutics Consumption Value Share by Type (2019-2024)
 Figure 28. Global Next Generation Antibody Therapeutics Market Share Forecast by Type (2025-2030)
 Figure 29. Global Next Generation Antibody Therapeutics Consumption Value Share by Application (2019-2024)
 Figure 30. Global Next Generation Antibody Therapeutics Market Share Forecast by Application (2025-2030)
 Figure 31. North America Next Generation Antibody Therapeutics Consumption Value Market Share by Type (2019-2030)
 Figure 32. North America Next Generation Antibody Therapeutics Consumption Value Market Share by Application (2019-2030)
 Figure 33. North America Next Generation Antibody Therapeutics Consumption Value Market Share by Country (2019-2030)
 Figure 34. United States Next Generation Antibody Therapeutics Consumption Value (2019-2030) & (USD Million)
 Figure 35. Canada Next Generation Antibody Therapeutics Consumption Value (2019-2030) & (USD Million)
 Figure 36. Mexico Next Generation Antibody Therapeutics Consumption Value (2019-2030) & (USD Million)
 Figure 37. Europe Next Generation Antibody Therapeutics Consumption Value Market Share by Type (2019-2030)
 Figure 38. Europe Next Generation Antibody Therapeutics Consumption Value Market Share by Application (2019-2030)
 Figure 39. Europe Next Generation Antibody Therapeutics Consumption Value Market Share by Country (2019-2030)
 Figure 40. Germany Next Generation Antibody Therapeutics Consumption Value (2019-2030) & (USD Million)
 Figure 41. France Next Generation Antibody Therapeutics Consumption Value (2019-2030) & (USD Million)
 Figure 42. United Kingdom Next Generation Antibody Therapeutics Consumption Value (2019-2030) & (USD Million)
 Figure 43. Russia Next Generation Antibody Therapeutics Consumption Value (2019-2030) & (USD Million)
 Figure 44. Italy Next Generation Antibody Therapeutics Consumption Value (2019-2030) & (USD Million)
 Figure 45. Asia-Pacific Next Generation Antibody Therapeutics Consumption Value Market Share by Type (2019-2030)
 Figure 46. Asia-Pacific Next Generation Antibody Therapeutics Consumption Value Market Share by Application (2019-2030)
 Figure 47. Asia-Pacific Next Generation Antibody Therapeutics Consumption Value Market Share by Region (2019-2030)
 Figure 48. China Next Generation Antibody Therapeutics Consumption Value (2019-2030) & (USD Million)
 Figure 49. Japan Next Generation Antibody Therapeutics Consumption Value (2019-2030) & (USD Million)
 Figure 50. South Korea Next Generation Antibody Therapeutics Consumption Value (2019-2030) & (USD Million)
 Figure 51. India Next Generation Antibody Therapeutics Consumption Value (2019-2030) & (USD Million)
 Figure 52. Southeast Asia Next Generation Antibody Therapeutics Consumption Value (2019-2030) & (USD Million)
 Figure 53. Australia Next Generation Antibody Therapeutics Consumption Value (2019-2030) & (USD Million)
 Figure 54. South America Next Generation Antibody Therapeutics Consumption Value Market Share by Type (2019-2030)
 Figure 55. South America Next Generation Antibody Therapeutics Consumption Value Market Share by Application (2019-2030)
 Figure 56. South America Next Generation Antibody Therapeutics Consumption Value Market Share by Country (2019-2030)
 Figure 57. Brazil Next Generation Antibody Therapeutics Consumption Value (2019-2030) & (USD Million)
 Figure 58. Argentina Next Generation Antibody Therapeutics Consumption Value (2019-2030) & (USD Million)
 Figure 59. Middle East & Africa Next Generation Antibody Therapeutics Consumption Value Market Share by Type (2019-2030)
 Figure 60. Middle East & Africa Next Generation Antibody Therapeutics Consumption Value Market Share by Application (2019-2030)
 Figure 61. Middle East & Africa Next Generation Antibody Therapeutics Consumption Value Market Share by Country (2019-2030)
 Figure 62. Turkey Next Generation Antibody Therapeutics Consumption Value (2019-2030) & (USD Million)
 Figure 63. Saudi Arabia Next Generation Antibody Therapeutics Consumption Value (2019-2030) & (USD Million)
 Figure 64. UAE Next Generation Antibody Therapeutics Consumption Value (2019-2030) & (USD Million)
 Figure 65. Next Generation Antibody Therapeutics Market Drivers
 Figure 66. Next Generation Antibody Therapeutics Market Restraints
 Figure 67. Next Generation Antibody Therapeutics Market Trends
 Figure 68. Porters Five Forces Analysis
 Figure 69. Next Generation Antibody Therapeutics Industrial Chain
 Figure 70. Methodology
 Figure 71. Research Process and Data Source

Companies Mentioned

Roche
Amgen
Pfizer
Takeda
Daiichi Sankyo
Seagen
Astellas
Immunomedics
GSK
Immunocore
ADC Therapeutics